索非布韦联合利巴韦林治疗肝移植术后丙型病毒性肝炎复发:附1例报告

张静; 张胥丰; 刘学民; 刘正稳; 吕毅

doi:10.3969/j.issn.1674-7445.2016.01.012

索非布韦联合利巴韦林治疗肝移植术后丙型病毒性肝炎复发:附1例报告

doi: 10.3969/j.issn.1674-7445.2016.01.012

710061 西安交通大学医学部第一附属医院肝胆外科

基金项目:

国家自然科学基金 81470896

详细信息

通讯作者:
吕毅, Email:luyi169@126.com

中图分类号: R617;R512.6⁺3
计量
- 文章访问数: 142
- HTML全文浏览量: 107
- PDF下载量: 7
- 被引次数: 0
出版历程
- 收稿日期: 2015-10-11
- 网络出版日期: 2021-01-19
- 刊出日期: 2016-01-15

摘要

摘要: 报道1例通过自行服用索非布韦+利巴韦林成功治疗肝移植术后丙型病毒性肝炎(丙肝)复发的个案, 为肝移植术后丙肝复发的治疗提供参考, 以延长移植肝的存活时间, 改善患者的预后。索非布韦+利巴韦林方案能快速有效地降低肝移植术后血清丙型肝炎病毒(HCV)RNA定量, 消除病毒对移植肝损伤, 因此可作为肝移植术后丙肝复发的有效治疗手段, 但仍需密切观察白细胞减低等不良反应的发生情况。
- 索非布韦 /
- 利巴韦林 /
- 肝移植 /
- 丙型病毒性肝炎 /
- 丙型肝炎病毒

HTML全文

图 1 本例患者HCV RNA定量的变化

Figure 1. Change of HCV RNA quantification of the patient

下载: 全尺寸图片幻灯片

参考文献(14)

[1]	Gurusamy KS, Tsochatzis E, Toon CD. Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation[J]. Cochrane Database Syst Rev, 2013, 12:CD006573. https://www.ncbi.nlm.nih.gov/pubmed/24297303
[2]	Crespo G, Mariño Z, Navasa M. Viral hepatitis in liver transplantation[J]. Gastroenterology, 2012, 142(6):1373-1383. doi: 10.1053/j.gastro.2012.02.011
[3]	Joshi D, Pinzani M, Carey I. Recurrent HCV after liver transplantation-mechanisms, assessment and therapy[J]. Nat Rev Gastroenterol Hepatol, 2014, 11(12):710-721. doi: 10.1038/nrgastro.2014.114
[4]	AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance:AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus[J]. Hepatology, 2015, 62(3):932-954. doi: 10.1002/hep.27950
[5]	Jacobson IM, Gordon SC, Kowdley KV. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options[J]. N Engl J Med, 2013, 368(20):1867-1877. doi: 10.1056/NEJMoa1214854
[6]	Lawitz E, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection[J]. N Engl J Med, 2013, 369(7):678-679. doi: 10.1056/NEJMc1307641
[7]	O'Leary JG, Randall H, Onaca N. Post-liver transplant survival in hepatitis C patients is improving over time[J]. Liver Transpl, 2009, 15(4):360-368. doi: 10.1002/lt.v15:4
[8]	Burton JR Jr, O'Leary JG, Verna EC. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy[J]. J Hepatol, 2014, 61(3):508-514. doi: 10.1016/j.jhep.2014.04.037
[9]	Vitale A, Spolverato G, Burra P. Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation[J]. Transpl Int, 2015, 28(9):1055-1065. doi: 10.1111/tri.2015.28.issue-9
[10]	Charlton M, Gane E, Manns MP. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation[J]. Gastroenterology, 2015, 148(1):108-117. doi: 10.1053/j.gastro.2014.10.001
[11]	Lens S, Gambato M, Londoño MC. Interferon-free regimens in the liver-transplant setting[J]. Semin Liver Dis, 2014, 34(1):58-71. doi: 10.1055/s-00000069
[12]	Welsch C, Jesudian A, Zeuzem S. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives[J]. Gut, 2012, 61(Suppl 1):i36-i46. https://www.ncbi.nlm.nih.gov/pubmed/22504918
[13]	Forns X, Charlton M, Denning J. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation[J]. Hepatology, 2015, 61(5):1485-1494. doi: 10.1002/hep.27681
[14]	Zeng QL, Zhang JY, Zhang Z. Sofosbuvir and ABT-450:terminator of hepatitis C virus?[J]. World J Gastroenterol, 2013, 19(21):3199-3206. doi: 10.3748/wjg.v19.i21.3199